Opioid drug to be distributed via program to deter misuse
Monday, January 10, 2011 (Last Updated: 01/11/2011)
MONDAY, Jan. 10 (HealthDay News) -- Fentanyl (Abstral) tablets have been approved by the U.S. Food and Drug Administration to help opioid-tolerant adults with cancer manage breakthrough pain.
Only doctors skilled in the use of Schedule II opioids should prescribe this product, the FDA said in a news release. Any pharmacy, distributor or health-care professional involved in Abstral's distribution or use will have to enroll in a Risk Evaluation and Mitigation Strategy (REMS) program, designed to minimize misuse and abuse, the agency added.
Abstral's safety was evaluated in clinical studies involving 311 opioid-tolerant cancer patients with breakthrough pain. The most common side effects included nausea, constipation, drowsiness, and headache.
The FDA warned that the risk of death had been cited in studies of similar immediate-release fentanyl products. "The deaths occurred as a result of improper patient selection and/or improper dosing," according to an FDA statement.
Abstral is produced by ProStraken Inc., based in Bedminster, N.J.
To learn more about fentanyl, visit the U.S. National Institute on Drug Abuse.
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.
September 03, 2014
November 25, 2015